Low evidence of radiation therapy in prostate cancer: A plea for intensified scientific activity

Acta Oncologica

Volumn 43, Issue 4, 2004, Pages 311-315

  Glimelius, Bengt ^a   Steineck, Gunnar ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; DEFECATION DISORDER; EDITORIAL; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FECAL LEAKAGE; FLATULENCE; HUMAN; INTESTINE INJURY; ONCOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; URINE INCONTINENCE;

AGED; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3042800885     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410032867     Document Type: Editorial

References (50)

1. Bentzen SM. From clincal trials to clinical practice: A user's guide to evidence-based oncology. Eur J Cancer Suppl 2003; 1: 77-91.
2. Nygren P, Glimelius B. The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy-Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol 2001; 40: 155-65.
3. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evience-based medicine: What it is and what it is not. Br Med J 1996; 312: 71-2.
4. Steineck G, Kass PH, Ahlbom A. A comprehensive clinical epidemiological theory based on the concept of the source person-time and four distinct study stages. Acta Oncol 1998; 37: 15-23.
5. SBU - The Swedish Council on Technology Assessment in Health Care. Radiotherapy for cancer. Volume 1. Acta Oncol 1996; 35 (suppl 6): 1-100.
6. SBU - The Swedish Council on Technology Assessment in Health Care. Radiotherapy for Cancer. Volume 2: A critical review of the literature. Acta Oncol 1996; 35 (suppl 7): 1-152.
7. Frödin JE, Jonsson E, Möller T, Werkö L. Radiotherapy in Sweden - a study of present use in relation to the literature and estimate of future trends. Acta Oncol 1996; 35: 967-80.
8. Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types - summary and conclusions. Acta Oncol 2001; 40: 135-54.
9. Steineck G, Bergmark K, Henningsohn L, al-Abany M, Dickman PW, Helgason A. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol 2002; 41: 244-52.
10. Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 2003; 42: 443-61.
11. Ask A, Albertsson M, Järhult J, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in oesophageal cancer. Acta Oncol 2003; 42: 462-75.
12. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-ståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-92.
13. Sirzen F, Kjellen E, Sörenson S, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003; 42: 493-515.
14. Strander H, Turesson I, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol 2003; 42: 516-31.
15. Rutqvist LE, Rose C, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol 2003; 42: 532-45.
16. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol 2003; 42: 562-6.
17. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). Acta Oncol 2003; 42: 557-61.
18. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta Oncol 2003; 42: 546-56.
19. Widmark A, Flodgren P, Damber J, et al. A systemic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 2003; 42: 567-81.
20. Berg G, Blomquist E, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 2003; 42: 582-8.
21. Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 2003; 42: 605-19.
22. Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in Hodgkin's lymphoma. Acta Oncol 2003; 42: 589-604.
23. Falkmer U, Järhult J, Wersäll P, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42: 620-33.
24. Nilsson S, Widmark A, Norlén BJ. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316-81.
25. Bentzen SM. High-tech in radiation oncology: should there be a ceiling? Int J Radiat Oncol Biol Phys 2004; 58: 320-30.
26. Zietman AL. Dose escalation in localized prostate cancer: make no assumptions. Int J Radiat Oncol Biol Phys 2002; 54: 635-6.
27. Johansson KA, Mattsson S, Brahme A, Carlsson J, Zackrisson B, Turesson I. Radiation therapy dose delivery. Acta Oncol 2003; 42: 85-91.
28. Roach M, 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11.
29. Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys 2003; 55: 51-63.
30. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9.
31. Adolfsson J, Oksanen H, Salo JO, Steineck G. Localized prostate cancer and 30 years of follow-up in a population-based setting. Prostate Cancer Prostatic Dis 2000; 3: 37-42.
32. Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993; 72: 310-22.
33. Steineck G, Adolfsson J. Bias due to observation of different parts of a nonconstant hazard curve over time. Urology 1996; 48: 105-9.
34. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-6.
35. Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 2002; 94: 862-71.
36. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 2003; 62: 707-13.
37. Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998; 51: 991-7.
38. Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: Comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001; 49: 51-9.
39. Yeoh EE, Botten R, Russo A, et al. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys 2000; 47: 915-24.
40. al-Abany M, Helgason AR, Ågren-Cronquist A-K, Lind B, Mavroidis P, et al. Dose to the anal sphincter region and risk of fecal leakage. Acta Oncol 2004; 43: 117-8.
41. Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003; 21: 830-5.
42. Cassileth B. Clinical trials: Time for action. J Clin Oncol 2003; 21: 765-6.
43. Glatstein E. What is research? Int J Radiat Oncol Biol Phys 2001; 51: 288-90.
44. Zackrisson B, Mattsson S, Kjellén E, Glimelius B. and the Swedish Cancer Society Investigation Group. Research and development of radiation therapy in clinical routines. Acta Oncol 2003; 42: 115-122.
45. Mattsson S, Brahme A, Carlsson J, et al. Swedish Cancer Society radiation therapy research investigation. Acta Oncol 2002; 41: 596-603.
46. Medical Research Council. Clinical research-crisis and costs (in Swedish). MFR Report 5, 1998.
47. Swedish Cancer Society. Investigation concerning clinical treatment studies. Cancerfonden, 1999 (in Swedish).
48. Forssell-Aronsson E, Kjellén E, Mattsson S, Hellström M. and the Swedish Cancer Society Investigation Group. Medical imaging for improved tumour characterisation, delineation and treatment verification. Acta Oncol 2002; 41: 604-14.
49. Turesson I, Carlsson J, Brahme A, Glimelius B, Zackrisson B, Stenerlow B. and the Swedish Cancer Society Investigation Group. Biological response to radiation therapy. Acta Oncol 2003; 42: 92-106.
50. Coleman CN. International Conference on Translational Research ICTR 2003 Conference Summary: marshalling resources in a complex time. Int J Radiat Oncol Biol Phys 2004; 58: 307-19.